ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $6.80.
A number of brokerages recently commented on PRQR. Oppenheimer began coverage on ProQR Therapeutics in a research note on Thursday, March 12th. They issued an "outperform" rating and a $9.00 target price for the company. Wall Street Zen upgraded ProQR Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Saturday, March 14th. Citigroup restated a "market outperform" rating on shares of ProQR Therapeutics in a research note on Friday, March 13th. Weiss Ratings restated a "sell (d-)" rating on shares of ProQR Therapeutics in a research note on Tuesday. Finally, Chardan Capital restated a "buy" rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday, April 9th.
Get Our Latest Analysis on PRQR
Institutional Trading of ProQR Therapeutics
A number of large investors have recently bought and sold shares of PRQR. Aberdeen Group plc grew its position in ProQR Therapeutics by 28.4% in the fourth quarter. Aberdeen Group plc now owns 2,950,676 shares of the biopharmaceutical company's stock valued at $5,960,000 after acquiring an additional 651,853 shares during the period. Ikarian Capital LLC grew its position in ProQR Therapeutics by 67.2% in the fourth quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company's stock valued at $3,014,000 after acquiring an additional 600,000 shares during the period. Privium Fund Management B.V. grew its position in ProQR Therapeutics by 7.2% in the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company's stock valued at $10,823,000 after acquiring an additional 359,475 shares during the period. Citadel Advisors LLC grew its position in ProQR Therapeutics by 73.2% in the third quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company's stock valued at $1,399,000 after acquiring an additional 277,749 shares during the period. Finally, Millennium Management LLC grew its position in ProQR Therapeutics by 80.8% in the fourth quarter. Millennium Management LLC now owns 434,991 shares of the biopharmaceutical company's stock valued at $879,000 after acquiring an additional 194,369 shares during the period. 32.65% of the stock is currently owned by institutional investors.
ProQR Therapeutics Trading Down 4.9%
Shares of NASDAQ PRQR opened at $1.55 on Friday. The business has a fifty day simple moving average of $1.68 and a 200 day simple moving average of $1.96. The firm has a market capitalization of $163.31 million, a price-to-earnings ratio of -3.37 and a beta of 0.10. ProQR Therapeutics has a one year low of $1.33 and a one year high of $3.10.
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). The firm had revenue of $5.53 million during the quarter, compared to analyst estimates of $6.12 million. ProQR Therapeutics had a negative net margin of 255.83% and a negative return on equity of 65.89%. On average, research analysts anticipate that ProQR Therapeutics will post -0.53 earnings per share for the current fiscal year.
About ProQR Therapeutics
(
Get Free Report)
ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company's pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.
Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ProQR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProQR Therapeutics wasn't on the list.
While ProQR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
